Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

16 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The impact of CD56 expression in smoldering myeloma patients on early progression.
Notarfranchi L, Segreto R, Vescovini R, Dalla Palma AB, Marchica V, Burroughs-Garcia J, Toscani D, Todaro G, Raimondi V, Iannozzi NT, Bonomini S, Sammarelli G, Craviotto L, Pedrazzoni M, Storti P, Giuliani N. Notarfranchi L, et al. Hematol Oncol. 2023 Aug;41(3):587-589. doi: 10.1002/hon.3104. Epub 2022 Dec 1. Hematol Oncol. 2023. PMID: 36441875 No abstract available.
Lenalidomide increases human dendritic cell maturation in multiple myeloma patients targeting monocyte differentiation and modulating mesenchymal stromal cell inhibitory properties.
Costa F, Vescovini R, Bolzoni M, Marchica V, Storti P, Toscani D, Accardi F, Notarfranchi L, Dalla Palma B, Manferdini C, Manni S, Todaro G, Lisignoli G, Piazza F, Aversa F, Giuliani N. Costa F, et al. Among authors: notarfranchi l. Oncotarget. 2017 May 23;8(32):53053-53067. doi: 10.18632/oncotarget.18085. eCollection 2017 Aug 8. Oncotarget. 2017. PMID: 28881793 Free PMC article.
Bone marrow Dikkopf-1 levels are a new independent risk factor for progression in patients with smouldering myeloma.
Dalla Palma B, Marchica V, Pedrazzoni M, Accardi F, Notarfranchi L, Goldoni M, De Luca F, Costa F, Storti P, Toscani D, Sammarelli G, Bonomini S, Aversa F, Giuliani N. Dalla Palma B, et al. Among authors: notarfranchi l. Br J Haematol. 2018 Dec;183(5):812-815. doi: 10.1111/bjh.15026. Epub 2017 Nov 16. Br J Haematol. 2018. PMID: 29143308 Free article. No abstract available.
A Rare Case of Systemic AL Amyloidosis with Muscle Involvement: A Misleading Diagnosis.
Accardi F, Papa V, Capozzi AR, Capello GL, Verga L, Mancini C, Martella E, Costa R, Notarfranchi L, Dalla Palma B, Aversa F, Pietrini V, Cenacchi G, Giuliani N. Accardi F, et al. Among authors: notarfranchi l. Case Rep Hematol. 2018 Jan 31;2018:9840405. doi: 10.1155/2018/9840405. eCollection 2018. Case Rep Hematol. 2018. PMID: 29651353 Free PMC article.
Neurofibromatosis type I and multiple myeloma coexistence: A possible link?
Accardi F, Marchica V, Mancini C, Maredi E, Racano C, Notarfranchi L, Martorana D, Storti P, Martella E, Palma BD, Craviotto L, Filippo M, Percesepe A, Aversa F, Giuliani N. Accardi F, et al. Among authors: notarfranchi l. Hematol Rep. 2018 Apr 3;10(1):7457. doi: 10.4081/hr.2018.7457. eCollection 2018 Mar 2. Hematol Rep. 2018. PMID: 29721253 Free PMC article.
Application of Next-Generation Sequencing for the Genomic Characterization of Patients with Smoldering Myeloma.
Manzoni M, Marchica V, Storti P, Ziccheddu B, Sammarelli G, Todaro G, Pelizzoni F, Salerio S, Notarfranchi L, Pompa A, Baldini L, Bolli N, Neri A, Giuliani N, Lionetti M. Manzoni M, et al. Among authors: notarfranchi l. Cancers (Basel). 2020 May 23;12(5):1332. doi: 10.3390/cancers12051332. Cancers (Basel). 2020. PMID: 32456143 Free PMC article.
PD-L1/PD-1 Pattern of Expression Within the Bone Marrow Immune Microenvironment in Smoldering Myeloma and Active Multiple Myeloma Patients.
Costa F, Vescovini R, Marchica V, Storti P, Notarfranchi L, Dalla Palma B, Toscani D, Burroughs-Garcia J, Catarozzo MT, Sammarelli G, Giuliani N. Costa F, et al. Among authors: notarfranchi l. Front Immunol. 2021 Jan 8;11:613007. doi: 10.3389/fimmu.2020.613007. eCollection 2020. Front Immunol. 2021. PMID: 33488620 Free PMC article.
Phase II Trial of Maintenance Treatment With IL2 and Zoledronate in Multiple Myeloma After Bone Marrow Transplantation: Biological and Clinical Results.
Fazzi R, Petrini I, Giuliani N, Morganti R, Carulli G, Dalla Palma B, Notarfranchi L, Galimberti S, Buda G. Fazzi R, et al. Among authors: notarfranchi l. Front Immunol. 2021 Feb 3;11:573156. doi: 10.3389/fimmu.2020.573156. eCollection 2020. Front Immunol. 2021. PMID: 33613510 Free PMC article. Clinical Trial.
16 results